- Home
- EXAI vs CVAC Comparison
EXAI vs CVAC Comparison
Compare EXAI & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAI
- CVAC
- Stock Information
- Founded
- EXAI 2012
- CVAC 2000
- Country
- EXAI United Kingdom
- CVAC Germany
- Employees
- EXAI N/A
- CVAC N/A
- Industry
- EXAI Biotechnology: Biological Products (No Diagnostic Substances)
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- EXAI Health Care
- CVAC Health Care
- Exchange
- EXAI Nasdaq
- CVAC Nasdaq
- Market Cap
- EXAI 613.6M
- CVAC 637.1M
- IPO Year
- EXAI 2021
- CVAC 2020
- Fundamental
- Price
- EXAI $4.84
- CVAC $2.56
- Analyst Decision
- EXAI Hold
- CVAC Hold
- Analyst Count
- EXAI 4
- CVAC 3
- Target Price
- EXAI $7.00
- CVAC $10.00
- AVG Volume (30 Days)
- EXAI 828.8K
- CVAC 556.8K
- Earning Date
- EXAI 11-08-2024
- CVAC 11-12-2024
- Dividend Yield
- EXAI N/A
- CVAC N/A
- EPS Growth
- EXAI N/A
- CVAC N/A
- EPS
- EXAI N/A
- CVAC N/A
- Revenue
- EXAI $22,877,630.00
- CVAC $70,565,734.00
- Revenue This Year
- EXAI $156.33
- CVAC $123.97
- Revenue Next Year
- EXAI N/A
- CVAC N/A
- P/E Ratio
- EXAI N/A
- CVAC N/A
- Revenue Growth
- EXAI N/A
- CVAC 75.11
- 52 Week Low
- EXAI $3.80
- CVAC $2.22
- 52 Week High
- EXAI $7.91
- CVAC $6.30
- Technical
- Relative Strength Index (RSI)
- EXAI 44.03
- CVAC 39.24
- Support Level
- EXAI $4.45
- CVAC $2.37
- Resistance Level
- EXAI $4.85
- CVAC $2.65
- Average True Range (ATR)
- EXAI 0.38
- CVAC 0.18
- MACD
- EXAI -0.07
- CVAC -0.02
- Stochastic Oscillator
- EXAI 19.12
- CVAC 31.67
About EXAI Exscientia Plc
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.